GSS: End of Proposed Merger with Microba Life Sciences
Released
Released
Announcement PDF
Genetic Signatures Ltd ABN 30 095 913 205
7 Eliza Street, Newtown NSW 2042
Telephone + 61 (2) 9870 7580
1
ASX Announcement 18 November 2026
GSS not proceeding with Proposed Merger with Microba Life Sciences
Genetic Signatures Limited (ASX: GSS) (GSS) has resolved not to proceed with the Proposed Merger with
Microba Life Sciences Limited (ASX: MAP) (Microba) in light of Microba’s announcement that it will not
have financial capacity to complete the Proposed Merger without additional capital.
Genetic Signatures Limited (ASX: GSS) (GSS or the Company) refers to its announcement of 21 October 2026
which disclosed an update to the commercial terms of the proposed merger of GSS and Microba Life Sciences
Limited (ASX: MAP) (Microba) (Proposed Merger), as well as Microba’s request for a voluntary suspension of
trading in its shares dated 17 November 2026.
After many months of discussions, engagement and due diligence, GSS notifies the market that it is no longer
pursuing the Proposed Merger with Microba. Both GSS and Microba have invested a lot of time and effort into
pursuing the Proposed Merger. However, in light of Microba’s notification to the market that it does not have the
financial capacity to complete the Proposed Merger without additional capital, GSS has resolved not to proceed
with the Proposed Merger.
GSS notes that it had been in discussions with Microba regarding the possibility of providing unsecured debt
funding to assist Microba with its working capital requirements during the implementation of the Proposed Merger.
Ultimately, however, the GSS Board determined that it was not prepared to proceed with such an arrangement,
having regard to the risks associated and the potential regulatory requirements.
GSS will issue a separate announcement shortly formally withdrawing Resolution 4 from the Agenda of GSS’s
upcoming annual general meeting to be held on 30 November 2026.
GSS will also provide a further market announcement with respect to the impact of this announcement and the
withdrawal of Resolution 4 on the Takeovers Panel Application that was made by BCAL Diagnostics Limited on
13 November 2026.
This announcement has been authorised for release by the Board of Directors of Genetic Signatures Limited.
– END –
For further information contact:
Mike Aicher
Chair
Genetic Signatures
info@geneticsignatures.com
About Genetic Signatures
Genetic Signatures is a specialist molecular diagnostics company focused on the development and
commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a
suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases
under the EasyScreen™ brand. Genetic Signatures’ proprietary 3base® platform technology provides high-volume
hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree
of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are
major hospital and pathology laboratories undertaking infectious disease screening.
About Microba Life Sciences
Microba is at the forefront of microbiome health and human care. With world-leading science, insights and
collaboration tools, Microba’s vision is to deliver clinical-grade microbiome tests that help people live healthier,
happier lives. Better science. Better insights. Better health. Microba – Expect better. www.microba.com
Genetic Signatures Ltd ABN 30 095 913 205
7 Eliza Street, Newtown NSW 2042
Telephone + 61 (2) 9870 7580
2
Forward-looking statements
This announcement may contain certain ‘forward‐looking statements’ about the financial condition, results of
operations and business of GSS, and certain plans and objectives of the Board and management of GSS, including
in relation to the Proposed Merger. Forward‐looking statements can generally be identified by words such as ‘may’,
‘could’, ‘believes’, ‘plan’, ‘will’, ‘likely’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve
risks and uncertainties. These risks and uncertainties may include, but are not limited to, the outcome and effects
of the subject matter of this announcement, including whether the Proposed Merger will be implemented on the
revised terms or at all, its timing, the number of GSS securities to be issued, the ownership structure of GSS on
implementation, and the timing and content of the Further Addendum. You are cautioned not to place undue
reliance on forward‐looking statements, as actual outcomes may differ materially from them.
Any forward‐looking statements, opinions and estimates provided in this announcement necessarily involve
uncertainties, assumptions, contingencies and other factors, and unknown risks may arise, many of which are
outside the control of GSS and Microba. The actual results, achievement or performance of GSS, Microba, or of
the combined group, may be materially different from any future results, achievement or performance expressed
or implied by such forward‐looking statements. Forward‐looking statements, including without limitation guidance
on future plans, are provided as a general guide only and should not be relied upon as an indication or guarantee
of future performance. Such forward‐looking statements speak only as of the date of this announcement. To the
maximum extent permitted by law, each of GSS and Microba disclaims any intent or obligation to update publicly
any forward‐looking statements, whether as a result of new information, future events or results or otherwise.
Share your feedback
Discover